Unknown

Dataset Information

0

Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19.


ABSTRACT: Type-I interferons (IFNs) mediate antiviral activity and have emerged as important immune mediators during coronavirus disease 19 (COVID-19). Several lines of evidence suggest that impaired type-I IFN signaling may predispose to severe COVID-19. However, the pathophysiologic mechanisms that contribute to illness severity remain unclear. In this study, our goal was to gain insight into how type-I IFNs influence outcomes in patients with COVID-19. To achieve this goal, we compared clinical outcomes between 26 patients with neutralizing type-I IFN autoantibodies (AAbs) and 192 patients without AAbs who were hospitalized for COVID-19 at three Italian hospitals. The presence of circulating AAbs to type-I IFNs was associated with an increased risk of admission to the intensive care unit and a delayed time to viral clearance. However, survival was not adversely affected by the presence of type-I IFN AAbs. Our findings provide further support for the role of type-I IFN AAbs in impairing host antiviral defense and promoting the development of critical COVID-19 pneumonia in severe acute respiratory syndrome coronavirus 2-infected individuals.

SUBMITTER: Abers MS 

PROVIDER: S-EPMC8444766 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| PRJNA561526 | ENA
| 41218 | ecrin-mdr-crc
| S-EPMC3359892 | biostudies-literature
| S-EPMC7856858 | biostudies-literature
| S-EPMC7713054 | biostudies-literature
| PRJNA562118 | ENA
| S-EPMC4118502 | biostudies-literature
| S-EPMC8014094 | biostudies-literature
| S-EPMC5532517 | biostudies-literature
| S-EPMC7836243 | biostudies-literature